Mission
Our strategy is to create an integrative, interdisciplinary platform to advance scientific discoveries that arise both in the lab and patient populations toward the ultimate goal of new knowledge that impacts patient care.
We integrate our clinical expertise, patient populations, and clinical samples from patients with advanced lung diseases (e.g., lung transplantation, lung fibrosis, chronic obstructive pulmonary disease [COPD], cystic fibrosis, pulmonary vascular diseases) and critical illness syndromes (e.g., acute lung injury, sepsis, delirium, acute kidney injury, and major trauma) with our bench expertise to conduct state-of-the-art cellular, molecular, and animal translational studies. This approach facilitates a better understanding of the pathogenesis of lung diseases and allows us to develop novel therapeutics and biomarkers to better diagnose, prognosticate, and classify diseases at the molecular level.